CD38 Expression on CD8+ T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy

AIDS Research and Human Retroviruses

Volumn 20, Issue 2, 2004, Pages 227-233

  Benito, José Miguel ^a   López, Mariola ^a   Lozano, Sara ^a   Martinez, Pilar ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN;

ANTIGEN EXPRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCTION; REVIEW; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; MEMBRANE GLYCOPROTEINS; VIREMIA; VIRUS REPLICATION;

EID: 10744231165     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204773004950     Document Type: Review

References (34)

1. Prince H and Jensen E: Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immun Defic Syndr 1991;4:1227-1232.
2. Giorgi J and Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS Cohort study. Clin Immunol Immunopathol 1989;52:10-18.
3. Benito JM, Zabay J, Gil J, et al.: Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: Changes in the expression of CD45RO, CD45RA, CD38, CD11b, HLA-DR and CD25 antigens. J AIDS 1997;14:128-135.
4. Giorgi J, Liu Z, Hultin L, Cumberland W, Henessey K, and Detels R: Elevated levels of CD8+CD38+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years follow-up. J Acquir Immun Defic Syndr 1993;6:904-912.
5. Mocroft A, Bofill M, Lipman M, et al.: CD8+CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immun Defic Syndr 1997;14:158-162.
6. Carbone J, Gil J, Benito JM, et al.: Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000;14:2823-2829.
7. Liu Z, Cumberland W, Hultin L, Prince H, Detels R, and Giorgi J: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ T cell count, soluble activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immun Defic Syndr 1997;16:83-92.
8. Liu Z, Cumberland W, Hultin L, Kaplan A, Detels R, and Giorgi J: CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immun Defic Syndr 1998;18:332-340.
9. Giorgi J, Hultin L, McKeating J, et al.: Shorter survival in advanced HIV type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-870.
10. Bofill M, Mocroft A, Lipman M, et al.: Increased numbers of primed activated CD8+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-infected patients. AIDS 1996;10:827-834.
11. + lymphocyte activation in relation to viral load in HIV-infected patients with >400 CD4+ lymphocytes per microliter. AIDS Res Hum Retroviruses 1999;15:1419-1425.
12. Hultin L, Matud J, and Giorgi J: Quantitation of CD38 expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Cytometry 1998;33:123-132.
13. Orendi J, Bloem A, Borleffs J, et al.: Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma HIV-1 RNA level in HIV-1 infection. J Infect Dis 1998;178:1279-1287.
14. Kaufmann G, Zaunders J, Cunningham P, and Cooper D: Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. AIDS Res Hum Retroviruses 1999;15:963-972.
15. Bouscarat F, Levacher M, Landman R, et al.: Changes in blood CD8+ T lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998;12:1267-1273.
16. Bisset L, Cone R, Huber W, et al.: Highly active antiretroviral therapy durig early HIV infection reverses T-cell activation and maturation abnormalities. AIDS 1998;12:2115-2123.
17. Giorgi J, Majchrowicz M, Johnson T, Hultin P, Matud J, and Detels R: Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998;12:1833-1844.
18. Sondergaard S, Aladdin H, Ullum H, Gerstoft J, Skinhoj P, and Pedersen B: Immune function and phenotype before and after HAART. J Acquir Immun Defic Syndr 1999;21:376-383.
19. Cohen Stuart J, Hazenbergh M, Hamann D, et al.: The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immun Defic Syndr 2000;25:203-211.
20. Dornadula G, Zhang H, Van Uitert B, et al.: Residual HIV-RNA in the blood plasma of patients on suppressive HAART. JAMA 1999;282:1627-1632.
21. Mehta K, Shahid U, and Malavasi F: Human CD38: A cell-surface protein with multiple functions. FASEB J 1996;10:1408-1417.
22. Zaunders J, Carr A, McNally L, Peny R, and Cooper D: Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995;9:561-566.
23. Tilling R, Kinloch S, Goh L, et al.: Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple HAART in primary HIV infection. AIDS 2002;16:589-596.
24. Cossarizza A, Ortolani C, Mussini C, et al.: Massive activation of immune cells with an intact T cell repertoire in acute HIV syndrome. J Infect Dis 1995;172:105-112.
25. Tortajada C, García F, Plana M, et al: Comparison of T-cell subsets' reconstitution after 12 months of HAART initiated during early versus advanced states of HIV disease. J Acquir Immun Defic Syndr 2000;25:296-305.
26. Burgisser P, Hamman C, Kaufmann D, Battegay M, and Rutchsmann O: Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes toward normalization under treatment. The Swiss HIV cohort study. Clin Exp Immunol 1999;115:458-463.
27. Carcelain G, Blanc C, Leibowitch J, et al.: T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999;13:1077-1081.
28. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, and Landay A: Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000;14:761-770.
29. Dyrhol-Riise A, Voltersvik P, Olofsson J, and Asjo B: Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during HAART in early HIV-1 infection. AIDS 1999;13:2365-2376.
30. García F, Plana M, Vidal C, et al.: Dynamics of viral rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-F86.
31. Mandel T, Phipps R, Abbot A, et al.: The follicular dendritic cell: Long term antigen retention during immunity. Immunol Rev 1980;53:295-299.
32. Furtado M, Callaway D, Phair J, et al.: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
33. Zhang L, Ramratnam B, Tenner-Racz K, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
34. Sharkey M, Teo I, Greenough T, et al.: Persistence of episomal HIV-1 infection intermediates in patients on HAART. Nat Med 2000;6:76-81.